Stifel Nicolaus Believes Apellis Pharmaceuticals (NASDAQ: APLS) Won’t Stop Here

Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Apellis Pharmaceuticals (APLSResearch Report) today. The company’s shares closed last Wednesday at $63.20, close to its 52-week high of $66.07.

According to, Archila is a 4-star analyst with an average return of 7.2% and a 44.1% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.

Apellis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $77.33, representing a 22.0% upside. In a report issued on June 28, Needham also assigned a Buy rating to the stock with a $85.00 price target.

See today’s analyst top recommended stocks >>

Apellis Pharmaceuticals’ market cap is currently $5.11B and has a P/E ratio of -13.70. The company has a Price to Book ratio of 98.87.

Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.